VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes ...

ProteomeXchange’s 2026 update shows that global proteomics data sharing continues to accelerate, with more than 64,000 ...

Si Announces Two Customer Posters to be Presented at the American Association of Cancer Research Annual Meeting ...

As the “Method of the Year 2024”, spatial proteomics (SP) enables in situ characterization of protein localization, abundance ...

In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...

Despite major advances in targeted therapies, immunotherapies, and combination regimens, therapy resistance remains a central barrier to durable cancer ...

Chronic pain affects roughly 51 million adults in the United States alone, and for most of them, the available drug options ...

Research shows variants affecting the PAM enzyme may blunt the glucose-lowering effects of GLP-1 receptor agonists with ...

In this valuable study, the authors develop new approaches to investigate mRNA imprinting, a phenomenon in which RNA-protein complexes form in the nucleus to influence the fate of transcripts in the ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...

This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...